Latest On Paradigm Biopharmaceuticals Limited (PBIGF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-02-26 00:07 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-12-04 06:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 21:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 19:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-29 19:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 04:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 16:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 08:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-14 03:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 11:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 09:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 07:28 EST | Financials | Company financials have been released. | Neutral | |
About Paradigm Biopharmaceuticals Limited (PBIGF):
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
General
- Name Paradigm Biopharmaceuticals Limited
- Symbol PBIGF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndJune
- Web URLhttp://www.paradigmbiopharma.com
View More
Valuation
- Price/Book (Most Recent Quarter) 4.95
View More
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -20%
- Return on Equity -33%
- Revenue Per Share $0
- Gross Profit 3.65 million
- Quarterly Earnings Growth -69.2%
View More
Highlights
- Market Capitalization 456.16 million
View More
Share Statistics
- Shares Outstanding 228.07 million
- Shares Float 181.75 million
- % Held by Insiders 1849%
- % Held by Institutions 10.64%
View More
Technicals
- Beta 1.58
- 52 Week High $2.39
- 52 Week Low $0.86
- 50 Day Moving Average 1.8
- 200 Day Moving Average 2.03
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Paradigm Biopharmaceuticals Limited (PBIGF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Paradigm Biopharmaceuticals Limited (PBIGF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | -$0.04 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | -$0.03 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | -$0.01 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $412977 | -$0.01 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $412977 | -$0.01 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $1.48 million | -$0.01 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $1.48 million | -$0.03 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $1219.96 | -$0.03 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $14070 | -$0.01 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $1.33 million | -$0.01 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $1.33 million | -$0.01 | $0.00 | |
| 2017-12-31 | 2018-03-31 | -$0.01 | $0.00 | ||
| 2017-09-30 | 2017-12-31 | -$0.01 | $0.00 | ||
| 2017-06-30 | 2017-09-30 | -$0.01 | $0.00 | ||
| 2017-03-31 | 2017-06-30 | -$0.01 | $0.00 | ||
| 2016-12-31 | 2017-03-31 | -$0.01 | $0.00 | ||
| 2016-09-30 | 2016-12-31 | -$0.01 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | -$0.01 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$0.01 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.01 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.01 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$0.01 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.02 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.02 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.02 | $0.00 |
Paradigm Biopharmaceuticals Limited (PBIGF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | N/A | N/A |
| Selling General Administrative | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | N/A |
| Net Income Applicable to Common Shares | -10.37 million | -10.37 million | -3.6 million | -3.6 million | -3.6 million |
Cash Flow:
| Date | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 | Jan 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | 1.9 million |
| Change to Liabilities | 375513 | 375513 | 375513 | 375513 | N/A |
| Total Cash Flow from Investing Activities | 958996 | 958996 | 958996 | 958996 | 1.85 million |
| Net Borrowings | 919666 | 919666 | 919666 | 919666 | -18497 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | 390927 |
| Change to Operating Activities | -27634 | -27634 | -27634 | -27634 | N/A |
| Change in Cash | N/A | N/A | N/A | N/A | -701261 |
| Total Cash from Operating Activities | -2.1 million | -2.1 million | -2.1 million | -2.1 million | -2.94 million |
| Depreciation | N/A | N/A | N/A | N/A | 1129 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -1 million | -1 million | -1 million | -1 million | -292116 |
| Change to Net Income | 1.03 million | 1.03 million | 1.03 million | 1.03 million | -393773 |
| Capital Expenditures | N/A | N/A | N/A | N/A | 46589 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | N/A |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A | N/A | N/A |
| Common Stock | 146.51 million | 146.51 million | 145.87 million | N/A | 145.87 million |
| Other Current Assets | N/A | N/A | N/A | 145.87 million | N/A |
| Retained Earnings | -61.84 million | -61.84 million | -41.27 million | -41.27 million | -41.27 million |
| Other Liabilities | 89435 | 89435 | 68390 | 68390 | 68390 |
| Other Assets | 102616 | 102616 | 102616 | 102616 | 102616 |
| Cash | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | 5.06 million | 5.06 million | N/A | N/A | N/A |
| Other Stockholder Equity | 4.77 million | 4.77 million | 3.59 million | 3.59 million | 3.59 million |
| Property, Plant & Equipment | 871280 | 871280 | 942830 | 942830 | 942830 |
| Total Current Assets | 91.36 million | 91.36 million | N/A | N/A | N/A |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 86.5 million | 86.5 million | 105.23 million | 105.23 million | 105.23 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 4.34 million | 4.34 million | N/A | N/A | N/A |
Paradigm Biopharmaceuticals Limited (PBIGF) Chart:
Paradigm Biopharmaceuticals Limited (PBIGF) News:
Below you will find a list of latest news for Paradigm Biopharmaceuticals Limited (PBIGF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Paradigm Biopharmaceuticals Limited (PBIGF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Paradigm Biopharmaceuticals Limited (PBIGF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|